PureTech Health PLC on Tuesday said that a company it founded and in which it maintains a stake had begun trials of a new treatment for clostridioides difficile infection, in the hopes of moving.
Significant operational and clinical progress in 2023 and early 2024 with maturation of Internal Programs,1 launch of two new Founded Entities,2 including a $100 million Series A financing for.
Strong strategic and clinical progress in 2023, with multiple catalysts expected in 2024
Launching of two new Founded Entities to advance certain programs from the Wholly Owned Pipeline
Robust.
Live Biotherapeutic Product (LBP) Market worth $ 2 60 billion by 2030 - Exclusive Report by InsightAce Analytic newyorktelegraph.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newyorktelegraph.com Daily Mail and Mail on Sunday newspapers.